← Leaderboards
Eric C Holland
Sloan-Kettering Institute For Cancer Res
$32,588,073
Attributed
$35,797,932
Total exposure
22
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$64,826,326 · 27
By mechanism
U54$35,209,937 · 10
U01$11,468,348 · 4
R01$9,599,075 · 5
R35$5,450,329 · 1
P20$1,000,000 · 3
P30$968,410 · 1
Top collaborators
- Franziska Michor7 shared
- Dolores Hambardzumyan5 shared
- A. Mcgarry Houghton3 shared
- Christopher I Li3 shared
- Matthias Stephan3 shared
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Andrew Koff$7,486,650
- Robert I Benezra$12,794,451
- Marilyn D Resh$12,092,125
Others in their field
Top investigators on “Glioma”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$158,144,386
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
- David Heimbrook · Leidos Biomedical Research, Inc.$56,561,099
- Gregory H Reaman · National Childhood Cancer Foundation$49,046,612
- Melissa L Bondy · Stanford University$36,047,564
- Brad H. Pollock · University Of Florida$28,646,726
Research focus
GliomaMouse ModelTumorMalignant NeoplasmsCellsBiologyBrain NeoplasmsRadiationResponseGrantTumorigenesisBaseSignal TransductionBrainStemDesignResistanceIn VivoNeoplastic CellCell TypeMemberStem CellsLaboratoriesGenetically Engineered Mouse
Grant awards (118)
The role and mechanism of alternative RNA splice variants and gene fusions as drivers of cancer$1,056,000
R35 · FY2025 · CA · contact PI
The role and mechanism of alternative RNA splice variants and gene fusions as drivers of cancer$78,390
R35 · FY2025 · CA · contact PI
The role and mechanism of alternative RNA splice variants and gene fusions as drivers of cancer$78,390
R35 · FY2025 · CA · contact PI
The role and mechanism of alternative RNA splice variants and gene fusions as drivers of cancer$960,976
R35 · FY2024 · CA · contact PI
Exploring Drugs Targeting Hippo Pathway$78,390
R35 · FY2024 · CA · contact PI
The role and mechanism of alternative RNA splice variants and gene fusions as drivers of cancer$78,390
R35 · FY2024 · CA · contact PI
The role and mechanism of alternative RNA splice variants and gene fusions as drivers of cancer$839,885
R35 · FY2023 · CA · contact PI
The role and mechanism of alternative RNA splice variants and gene fusions as drivers of cancer$1,034,880
R35 · FY2022 · CA · contact PI
Precision disease prevention via somatic mutagenesis enumeration (PREDICTION)$471,680
U01 · FY2022 · ES · contact PI
The role and mechanism of alternative RNA splice variants and gene fusions as drivers of cancer$128,313
R35 · FY2022 · CA · contact PI
Biology and therapy of C11orf95-RELA fusion-driven ependymoma$125,104
U54 · FY2022 · CA · contact PI
The role and mechanism of alternative RNA splice variants and gene fusions as drivers of cancer$60,715
R35 · FY2022 · CA · contact PI
The role and mechanism of alternative RNA splice variants and gene fusions as drivers of cancer$570,838
R35 · FY2021 · CA · contact PI
The role and mechanism of alternative RNA splice variants and gene fusions as drivers of cancer$485,162
R35 · FY2021 · CA · contact PI
Precision disease prevention via somatic mutagenesis enumeration (PREDICTION)$319,373
U01 · FY2021 · ES · contact PI
Precision disease prevention via somatic mutagenesis enumeration (PREDICTION)$152,307
U01 · FY2021 · ES · contact PI
Biology and therapy of C11orf95-RELA fusion-driven ependymoma$41,230
U54 · FY2021 · CA · contact PI
Fred Hutch Preclinical 3T MRI$600,000
S10 · FY2020 · OD · contact PI
Evolution and Treatment Response of Brain, Breast, and Hematologic Malignancies$505,969
U54 · FY2020 · CA
Ultrasensitive measure of human mutagenesis: Connecting the exposome to disease$252,638
R01 · FY2020 · ES · contact PI
Ultrasensitive measure of human mutagenesis: Connecting the exposome to disease$143,362
R01 · FY2020 · ES · contact PI
Project 2: Molecular and Clinical Inputs Affecting Optimization of Glioma Therapy$126,492
U54 · FY2020 · CA · contact PI
Biology and therapy of C11orf95-RELA fusion-driven ependymoma$4,906,170
U54 · FY2019 · CA · contact PI
Evolution and Treatment Response of Brain, Breast, and Hematologic Malignancies$1,788,456
U54 · FY2019 · CA
Biology and therapy of C11orf95-RELA fusion-driven ependymoma$1,092,169
U54 · FY2019 · CA · contact PI
Project 2: Molecular and Clinical Inputs Affecting Optimization of Glioma Therapy$500,125
U54 · FY2019 · CA · contact PI
Admin Core$277,813
U54 · FY2019 · CA · contact PI
Critical role for a TrkB splice variant in oncogenic signaling$185,657
R21 · FY2019 · CA · contact PI
Early Phase Clinical Research Support$178,074
P30 · FY2019 · CA · contact PI
Early Phase Clinical Research Support$9,134
P30 · FY2019 · CA · contact PI
Early Phase Clinical Research Support$7,407
P30 · FY2019 · CA · contact PI
Early Phase Clinical Research Support$3,703
P30 · FY2019 · CA · contact PI
Early Phase Clinical Research Support$2,890
P30 · FY2019 · CA · contact PI
Evolution and Treatment Response of Brain, Breast, and Hematologic Malignancies$2,288,376
U54 · FY2018 · CA
Using genetically engineered mouse models of brain tumors to develop therapeutic nanoparticles & biomaterials$633,241
R01 · FY2018 · CA · contact PI
Project 2: Molecular and Clinical Inputs Affecting Optimization of Glioma Therapy$402,149
U54 · FY2018 · CA · contact PI
Critical role for a TrkB splice variant in oncogenic signaling$229,680
R21 · FY2018 · CA · contact PI
Early Phase Clinical Research Support$178,071
P30 · FY2018 · CA · contact PI
Early Phase Clinical Research Support$9,134
P30 · FY2018 · CA · contact PI
Early Phase Clinical Research Support$8,333
P30 · FY2018 · CA · contact PI
Early Phase Clinical Research Support$7,407
P30 · FY2018 · CA · contact PI
Early Phase Clinical Research Support$2,890
P30 · FY2018 · CA · contact PI
Early Phase Clinical Research Support$1,234
P30 · FY2018 · CA · contact PI
Evolution and Treatment Response of Brain, Breast, and Hematologic Malignancies$2,245,877
U54 · FY2017 · CA
Using genetically engineered mouse models of brain tumors to develop therapeutic nanoparticles & biomaterials$644,838
R01 · FY2017 · CA · contact PI
Project 2: Molecular and Clinical Inputs Affecting Optimization of Glioma Therapy$576,371
U54 · FY2017 · CA · contact PI
Early Phase Clinical Research Support$199,047
P30 · FY2017 · CA · contact PI
Evolution and Treatment Response of Brain, Breast, and Hematologic Malignancies$2,237,877
U54 · FY2016 · CA
Using genetically engineered mouse models of brain tumors to develop therapeutic nanoparticles & biomaterials$657,360
R01 · FY2016 · CA · contact PI
Project 2: Molecular and Clinical Inputs Affecting Optimization of Glioma Therapy$590,999
U54 · FY2016 · CA · contact PI
Non-neoplastic cell types dictate gliomagenesis and$549,607
U01 · FY2016 · CA
Early Phase Clinical Research Support$178,112
P30 · FY2016 · CA · contact PI
Evolution and Treatment Response of Brain, Breast, and Hematologic Malignancies$2,112,377
U54 · FY2015 · CA
Role of the Perivascular Microenvironment in Primary and Metastatic Brain Tumors$841,065
U54 · FY2015 · CA · contact PI
Non-neoplastic cell types dictate gliomagenesis and$591,607
U01 · FY2015 · CA
Project 2: Molecular and Clinical Inputs Affecting Optimization of Glioma Therapy$554,121
U54 · FY2015 · CA · contact PI
The Proneural Perivascular Niche and Therapeutic Response$213,026
U54 · FY2015 · CA · contact PI
Early Phase Clinical Research Support$182,974
P30 · FY2015 · CA · contact PI
Administrative Core$39,073
U54 · FY2015 · CA · contact PI
Role of the Perivascular Microenvironment in Primary and Metastatic Brain Tumors$934,250
U54 · FY2014 · CA · contact PI
Non-neoplastic cell types dictate gliomagenesis and$532,306
U01 · FY2014 · CA
The Proneural Perivascular Niche and Therapeutic Response$236,656
U54 · FY2014 · CA · contact PI
Administrative Core$43,292
U54 · FY2014 · CA · contact PI
Role of the Perivascular Microenvironment in Primary and Metastatic Brain Tumors$949,075
U54 · FY2013 · CA · contact PI
P3IK Signaling and Biology of Therapeutic Response in Brain and Prostate Tumors$725,951
U01 · FY2013 · CA · contact PI
Using mouse models to probe the relationship of oncogenesis to development and o$664,043
U01 · FY2013 · CA · contact PI
Non-neoplastic cell types dictate gliomagenesis and$515,843
U01 · FY2013 · CA
The Cell-Of-Origin of Human Cancers$403,421
U54 · FY2013 · CA · contact PI
The Role of Signaling Pathways in Brain Tumors in Mice$347,556
R01 · FY2013 · CA · contact PI
The Proneural Perivascular Niche and Therapeutic Response$240,436
U54 · FY2013 · CA · contact PI
The Role of Signaling Pathways in Brain Tumors in Mice$50,231
R01 · FY2013 · CA · contact PI
Administrative Core$43,869
U54 · FY2013 · CA · contact PI
Role of the Perivascular Microenvironment in Primary and Metastatic Brain Tumors$934,192
U54 · FY2012 · CA · contact PI
P3IK Signaling and Biology of Therapeutic Response in Brain and Prostate Tumors$818,272
U01 · FY2012 · CA · contact PI
Using mouse models to probe the relationship of oncogenesis to development and o$743,706
U01 · FY2012 · CA · contact PI
Non-neoplastic cell types dictate gliomagenesis and$591,519
U01 · FY2012 · CA
The Cell-Of-Origin of Human Cancers$431,467
U54 · FY2012 · CA · contact PI
The Role of Signaling Pathways in Brain Tumors in Mice$407,632
R01 · FY2012 · CA · contact PI
The Proneural Perivascular Niche and Therapeutic Response$236,782
U54 · FY2012 · CA · contact PI
Physical Science Oncology Center Training Program$114,890
T32 · FY2012 · CA · contact PI
Administrative Core$42,729
U54 · FY2012 · CA · contact PI
Role of the Perivascular Microenvironment in Primary and Metastatic Brain Tumors$964,830
U54 · FY2011 · CA · contact PI
P3IK Signaling and Biology of Therapeutic Response in Brain and Prostate Tumors$929,259
U01 · FY2011 · CA · contact PI
Using mouse models to probe the relationship of oncogenesis to development and o$743,710
U01 · FY2011 · CA · contact PI
The Role of Signaling Pathways in Brain Tumors in Mice$407,636
R01 · FY2011 · CA · contact PI
Tumor Microenvironment Interactions in Brain Tumors$1,111,508
U54 · FY2010 · CA · contact PI
P3IK Signaling and Biology of Therapeutic Response in Brain and Prostate Tumors$853,099
U01 · FY2010 · CA · contact PI
Using mouse models to probe the relationship of oncogenesis to development and o$688,149
U01 · FY2010 · CA · contact PI
The Role of Signaling Pathways in Brain Tumors in Mice$420,241
R01 · FY2010 · CA · contact PI
Infiltrating gliomas act to recruit stem cells$407,571
U54 · FY2010 · CA · contact PI
Tumor Microenvironment Interactions in Brain Tumors$1,503,474
U54 · FY2009 · CA · contact PI
P3IK Signaling and Biology of Therapeutic Response in Brain and Prostate Tumors$835,000
U01 · FY2009 · CA · contact PI
Using mouse models to probe the relationship of oncogenesis to development and o$742,917
U01 · FY2009 · CA · contact PI
Infiltrating gliomas act to recruit stem cells$551,169
U54 · FY2009 · CA · contact PI
The Role of Signaling Pathways in Brain Tumors in Mice$411,997
R01 · FY2009 · CA · contact PI
Tumor Microenvironment Interactions in Brain Tumors$1,122,151
U54 · FY2008 · CA · contact PI
Infiltrating gliomas act to recruit stem cells$411,290
U54 · FY2008 · CA · contact PI
Tumor Microenvironment Interactions in Brain Tumors$1,144,244
U54 · FY2007 · CA · contact PI
Pre-Clinical Trials of GEM Models for Gliomas$534,647
R01 · FY2007 · CA · contact PI
Infiltrating gliomas act to recruit stem cells$419,297
U54 · FY2007 · CA · contact PI
Requirements for generation and maintenance of gliomas$385,231
R01 · FY2007 · CA · contact PI
Tumor Microenvironment Interactions in Brain Tumors$1,180,000
U54 · FY2006 · CA · contact PI
Pre-Clinical Trials of GEM Models for Gliomas$557,604
R01 · FY2006 · CA · contact PI
Infiltrating gliomas act to recruit stem cells$433,395
U54 · FY2006 · CA · contact PI
Requirements for generation and maintenance of gliomas$344,375
R01 · FY2006 · CA · contact PI
Pre-Clinical Trials of GEM Models for Gliomas$521,230
R01 · FY2005 · CA
Requirements for generation and maintenance of gliomas$352,663
R01 · FY2005 · CA
Pre-Clinical Trials of GEM Models for Gliomas$490,293
R01 · FY2004 · CA
Requirements for generation and maintenance of gliomas$352,663
R01 · FY2004 · CA
Pre-Clinical Trials of GEM Models for Gliomas$560,077
R01 · FY2003 · CA
SPORE in Brain Cancer$500,000
P20 · FY2003 · CA
Requirements for generation and maintenance of gliomas$352,663
R01 · FY2003 · CA
Modeling the effects of INK4 alpha ARF loss on gliomas$256,725
R01 · FY2003 · CA
SPORE in Brain Cancer$500,000
P20 · FY2002 · CA
Modeling the effects of INK4 alpha ARF loss on gliomas$256,725
R01 · FY2002 · CA
Glial cell differentiation /low grade glioma formation$0
P20 · FY2002 · CA
Signal transduction blockade and high-grade gliioma$0
P20 · FY2002 · CA
Modeling the effects of INK4 alpha ARF loss on gliomas$257,447
R01 · FY2001 · CA